6jhs
From Proteopedia
(Difference between revisions)
m (Protected "6jhs" [edit=sysop:move=sysop]) |
|||
(3 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | The | + | ==The cryo-EM structure of HAV bound to a neutralizing antibody-F7== |
+ | <StructureSection load='6jhs' size='340' side='right'caption='[[6jhs]], [[Resolution|resolution]] 3.05Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[6jhs]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_hepatitis_A_virus_Hu/Australia/HM175/1976 Human hepatitis A virus Hu/Australia/HM175/1976] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6JHS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6JHS FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.05Å</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6jhs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6jhs OCA], [https://pdbe.org/6jhs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6jhs RCSB], [https://www.ebi.ac.uk/pdbsum/6jhs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6jhs ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, and F9-are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 muM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development. | ||
- | + | Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.,Cao L, Liu P, Yang P, Gao Q, Li H, Sun Y, Zhu L, Lin J, Su D, Rao Z, Wang X PLoS Biol. 2019 Apr 30;17(4):e3000229. doi: 10.1371/journal.pbio.3000229., eCollection 2019 Apr. PMID:31039149<ref>PMID:31039149</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 6jhs" style="background-color:#fffaf0;"></div> |
- | [[Category: | + | |
- | [[Category: | + | ==See Also== |
- | [[Category: | + | *[[Antibody 3D structures|Antibody 3D structures]] |
- | [[Category: | + | == References == |
- | [[Category: | + | <references/> |
- | [[Category: | + | __TOC__ |
- | [[Category: | + | </StructureSection> |
- | [[Category: | + | [[Category: Human hepatitis A virus Hu/Australia/HM175/1976]] |
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: | + | [[Category: Mus musculus]] |
+ | [[Category: Cao L]] | ||
+ | [[Category: Gao Q]] | ||
+ | [[Category: Li H]] | ||
+ | [[Category: Lin J]] | ||
+ | [[Category: Liu P]] | ||
+ | [[Category: Rao Z]] | ||
+ | [[Category: Su D]] | ||
+ | [[Category: Sun Y]] | ||
+ | [[Category: Wang X]] | ||
+ | [[Category: Yang P]] | ||
+ | [[Category: Zhu L]] |
Current revision
The cryo-EM structure of HAV bound to a neutralizing antibody-F7
|
Categories: Human hepatitis A virus Hu/Australia/HM175/1976 | Large Structures | Mus musculus | Cao L | Gao Q | Li H | Lin J | Liu P | Rao Z | Su D | Sun Y | Wang X | Yang P | Zhu L